In NSCLC, METTL3-mediated m6A modification increases the levels and stability of MALAT1, which acts as a ceRNA to abolish the gene silencing function of miR-1914-3p, and thereby increases the downstream target YAP, leading to NSCLC metastasis and drug resistance to cisplatin [61]. The gene discussed is METTL3; the disease is non-small cell lung carcinoma.